Related Experiment Video
Updated: Jun 12, 2025

Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Combination therapy of TKIs and ICIs for the treatment of anaplastic thyroid carcinoma
Xi Zhang1, Hongzhi Lu1, Yuanshi Lv1
1Department of Thyroid-head & Neck Oncosurgery-1, Jilin Cancer Hospital, Changchun, China.
Objective:
To explore the efficacy of combination therapy of tyrosine kinase inhibitor (TKIs) and immune checkpoint inhibitor (ICIs) in patients with anaplastic thyroid carcinoma (ATC).
Method:
This study enrolled 7 patients with ATC between June 2020 and June 2024, and conducted follow-up for a minimum of 6 months post-treatment, with the longest follow-up duration reaching 4 years. Patients received treatment with the TKI-Anlotinib and the ICI-Sintilimab, administered every 3 weeks in a treatment cycle.
Result:
Following treatment, among the 7 patients, the primary lesion in 3 patients who had not undergone thyroidectomy exhibited significant shrinkage, the lung metastases in 5 patients with pulmonary involvement significantly regressed, and the lateral cervical lymph node metastases in all patients demonstrated notable reduction.
Conclusion:
Combination therapy of TKIs and ICIs for the treatment of ATC patients can be highly effective and bringing better therapeutic outcomes and quality of life for patients.
More Related Videos
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Related Concept Videos
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF